Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Abstract: Rail defect detection (RDD) plays a crucial role in ensuring rail transportation safety. Recently, bimodal algorithms have become mainstream; however, the asymmetry in the information of RGB ...

Update: A minibus spending package passed by the House of Representatives on January 8, 2026, effectively cancels the Mars Sample Return program by eliminating almost all funding for future missions.

ABSTRACT: Enterprise application integration encounters substantial hurdles, particularly in intricate contexts that require elevated scalability and speed. Transactional applications directly ...

Investors sold out of the biotech following a quarterly earnings release this morning. The company posted a deeper-than-expected net loss. It's common for clinical-stage biotech companies to post net ...

Large language models (LLMs) have been extensively researched for programming-related tasks, including program summarisation, over recent years. However, the task of abstracting formal specifications ...

Language is often considered the hallmark of human intelligence, a complex system that enables us to share thoughts, express emotions, and convey intricate messages. For years, scientists believed ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...